기분부전장애 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 9.2%로 성장할 전망이며, 206억 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 지속성 우울증성 질환 유병률 상승, 인지도 및 진단율 향상, 항우울제 치료의 진보, 디지털 정신건강 솔루션의 채택 확대, 정신건강 치료에 대한 보험 적용범위 확대 등의 요인에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 AI 활용 정신건강 진단, 맞춤형 의료 및 약리 유전체, 디지털 치료 및 정신건강 앱, 원격 정신의료 및 원격 상담, 사이키델릭을 포함한 신규 항우울제 개발 등이 있습니다.
정신 건강 질환의 유병률 증가는 기분부전장애 시장의 확대를 촉진할 것으로 예측됩니다. 정신 질환이라고도 불리는 정신 건강 질환에는 기분, 사고, 행동에 영향을 미치는 폭넓은 질환이 포함됩니다. 끊임없는 업무 부담, 경제적 부담, 디지털 과다 등이 만성적인 불안으로 이어지는 현대 라이프스타일로 인한 지속적인 스트레스로 인해 정신건강 상태에 시달리는 사람들이 늘고 있습니다. 기분부전장애 치료는 기분을 안정시키고 감정적 회복력을 높이며 전체적인 행복감을 향상시키기 위해 약물요법, 라이프스타일 조정과 같은 장기적인 전략을 제공함으로써 정신건강을 돕습니다. 예를 들면, 미국을 거점으로 하는 단체인 National Alliance on Mental Illness는, 2024년 미국 18-44세 개인의 정신병 스펙트럼 및 기분장애 입원 건수는 연간 약 60만 건에 이르렀다고 보고했습니다.
헬스케어 시설의 성장은 기분부전장애 시장의 성장에 기여할 것으로 기대됩니다. 헬스케어 시설에는 효과적인 헬스케어 서비스를 제공하기 위해 필수불가결한 시스템, 리소스, 물리적 공간이 포함됩니다. 의료 요구가 진화함에 따라 헬스케어 시설의 증가는 진단 및 치료의 진보에 의해 초래되며, 복잡한 건강 상태를 관리하기 위해 업그레이드된 인프라가 필요합니다. 헬스케어 인프라는 의료시설, 훈련받은 전문가, 약제를 환자가 바로 이용할 수 있도록 함으로써 기분부전장애 치료를 돕습니다. 미국 비영리단체인 미국병원협회에 따르면 미국 병원 수는 2024년 6,120개로 2022년 6,093개에서 증가했습니다. 이러한 헬스케어 인프라의 확대는 기분 변조증 시장의 성장을 촉진하는 데 중요한 역할을 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 기분부전장애 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 기분부전장애 시장 : 성장률 분석
- 세계의 기분부전장애 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 기분부전장애 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 기분부전장애 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 기분부전장애 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 심리요법
- 약물요법
- 심리 요법 및 약물 요법의 조합
- 세계의 기분부전장애 시장 : 중증도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 경도
- 중간
- 심도
- 세계의 기분부전장애 시장 : 합병증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 불안장애
- 우울
- 약물 남용
- 세계의 기분부전장애 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 온라인
- 오프라인
- 세계의 기분부전장애 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 클리닉
- 세계의 기분부전장애 시장 : 심리요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 인지행동요법(CBT)
- 대인관계요법(IPT)
- 정신력 동적 요법
- 세계의 기분부전장애 시장 : 약물요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 항우울제(SSRI, SNRI, 삼환계 항우울제)
- 항정신병제
- 기분 안정제
- 세계의 기분부전장애 시장 : 심리요법 및 약물요법 조합 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 항우울제를 이용한 인지행동요법(CBT)
- 항정신병제를 이용한 대인관계요법(IPT)
- 기분 안정제를 이용한 정신력 동적 요법
제7장 지역별 및 국가별 분석
- 세계의 기분부전장애 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 기분부전장애 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 기분부전장애 시장 : 경쟁 구도
- 기분부전장애 시장 : 기업 프로파일
- Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- BristolMyers Squibb Company
- AstraZeneca plc
- Novartis International AG
- Roche Holding AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Biogen Inc.
- Horizon Therapeutics plc
- Shionogi & Co. Ltd.
- Jazz Pharmaceuticals
- Ipsen SA
- Cipla Limited
- Lupin Pharmaceuticals
- Mallinckrodt Pharmaceuticals
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 기분부전장애 시장(2029년) : 새로운 기회를 제공하는 국가
- 기분부전장애 시장(2029년) : 새로운 기회를 제공하는 부문
- 기분부전장애 시장(2029년) : 성장 전략
제36장 부록
AJY
Dysthymia, also referred to as persistent depressive disorder (PDD), is a chronic form of depression that lasts for at least two years (one year in children and adolescents). It is marked by a consistently low mood that persists for most of the time.
The main treatment options for dysthymia include psychotherapy, pharmacotherapy, and a combination of both. Psychotherapy involves working with a mental health professional to manage and address the condition. The severity of dysthymia can range from mild to moderate to severe, often accompanied by comorbidities such as anxiety disorders, depression, and substance abuse. These treatments are available through various distribution channels, both online and offline, and are utilized by a range of end-users, including hospitals and clinics.
The dysthymia market research report is one of a series of new reports from The Business Research Company that provides dysthymia market statistics, including the dysthymia industry global market size, regional shares, competitors with the dysthymia market share, detailed dysthymia market segments, market trends, and opportunities, and any further data you may need to thrive in the dysthymia industry. This dysthymia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dysthymia market size has grown strongly in recent years. It will grow from $13.25 billion in 2024 to $14.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth observed in the historic period can be attributed to factors such as rising awareness of mental health disorders, advancements in antidepressant medications, the increasing prevalence of chronic depression, improved access to healthcare and therapy, and evolving diagnostic criteria in psychiatry.
The dysthymia market size is expected to see strong growth in the next few years. It will grow to $20.60 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth expected during the forecast period can be attributed to factors such as the rising prevalence of persistent depressive disorder, increasing awareness and diagnosis rates, advancements in antidepressant therapies, greater adoption of digital mental health solutions, and expanding insurance coverage for mental health treatments. Key trends in the forecast period include AI-driven mental health diagnostics, personalized medicine and pharmacogenomics, digital therapeutics and mental health apps, telepsychiatry and remote counseling, and the development of novel antidepressant drugs, including psychedelics.
The growing prevalence of mental health disorders is expected to drive the expansion of the dysthymia market. Mental health disorders, also referred to as psychiatric or mental illnesses, include a wide range of conditions that impact mood, thinking, and behavior. People are increasingly suffering from mental health conditions due to ongoing stress from modern lifestyles, where constant work pressures, financial strains, and digital overload lead to chronic anxiety. Dysthymia treatment supports mental health by offering long-term strategies such as therapy, medication, and lifestyle adjustments to stabilize mood, enhance emotional resilience, and improve overall well-being. For example, in 2024, the National Alliance on Mental Illness, a US-based organization, reported that psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations annually among individuals aged 18-44 in the U.S. Thus, the rising prevalence of mental health disorders is fueling the growth of the dysthymia market.
The growth of healthcare facilities is expected to contribute to the growth of the dysthymia market. Healthcare facilities include the essential systems, resources, and physical spaces needed to provide effective healthcare services. As medical needs evolve, the increase in healthcare facilities is driven by advancements in diagnostics and treatments, which require upgraded infrastructure to manage complex health conditions. Healthcare infrastructure supports dysthymia treatment by ensuring that medical facilities, trained professionals, and medication are readily available to patients. According to the American Hospital Association, a US-based non-profit organization, the United States had 6,120 hospitals in 2024, an increase from 6,093 hospitals in 2022. This expansion of healthcare infrastructure is playing a key role in driving the growth of the dysthymia market.
In July 2023, Big Health Inc., a US-based digital health company specializing in mental health technology, acquired Limbix Health Inc. for an undisclosed amount. This acquisition expands Big Health's range of non-drug treatment options, particularly in the area of VR-based therapeutics for mental health conditions such as depression and anxiety. Limbix Health, a US-based digital therapeutics company, uses virtual reality (VR) technology to treat mental health disorders, including dysthymia.
Major players in the dysthymia market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, BristolMyers Squibb Company, AstraZeneca plc, Novartis International AG, Roche Holding AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Biogen Inc., Horizon Therapeutics plc, Shionogi & Co. Ltd., Jazz Pharmaceuticals, Ipsen SA, Cipla Limited, Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals.
North America was the largest region in the dysthymia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysthymia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dysthymia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dysthymia market consists of revenues earned by entities by providing treatment such as mindfulness-based therapy, interpersonal therapy (IPT), and cognitive behavioral therapy (CBT). The market value includes the value of related goods sold by the service provider or included within the service offering. The dysthymia market also includes sales of antidepressant medications, psychotherapy tools, digital therapeutics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dysthymia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dysthymia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dysthymia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysthymia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Psychotherapy; Pharmacotherapy; Combination Of Psychotherapy And Pharmacotherapy
- 2) By Severity: Mild; Moderate; Severe
- 3) By Comorbidities: Anxiety Disorders; Depression; Substance Abuse
- 4) By Distribution Channel: Online; Offline
- 5) By End-Users: Hospitals; Clinics
- Sub Segments:
- 1) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Interpersonal Therapy (IPT); Psychodynamic Therapy
- 2) By Pharmacotherapy: Antidepressants (SSRIs, SNRIs, Tricyclic Antidepressants); Antipsychotics; Mood Stabilizers
- 3) By Combination of Psychotherapy and Pharmacotherapy: Cognitive Behavioral Therapy (CBT) with Antidepressants; Interpersonal Therapy (IPT) with Antipsychotics; Psychodynamic Therapy with Mood Stabilizers
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Sanofi SA
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dysthymia Market Characteristics
3. Dysthymia Market Trends And Strategies
4. Dysthymia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Dysthymia Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dysthymia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dysthymia Market Growth Rate Analysis
- 5.4. Global Dysthymia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dysthymia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dysthymia Total Addressable Market (TAM)
6. Dysthymia Market Segmentation
- 6.1. Global Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Psychotherapy
- Pharmacotherapy
- Combination Of Psychotherapy And Pharmacotherapy
- 6.2. Global Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Mild
- Moderate
- Severe
- 6.3. Global Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anxiety Disorders
- Depression
- Substance Abuse
- 6.4. Global Dysthymia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Online
- Offline
- 6.5. Global Dysthymia Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- 6.6. Global Dysthymia Market, Sub-Segmentation Of Psychotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cognitive Behavioral Therapy (CBT)
- Interpersonal Therapy (IPT)
- Psychodynamic Therapy
- 6.7. Global Dysthymia Market, Sub-Segmentation Of Pharmacotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antidepressants (SSRIs, SNRIs, Tricyclic Antidepressants)
- Antipsychotics
- Mood Stabilizers
- 6.8. Global Dysthymia Market, Sub-Segmentation Of Combination of Psychotherapy and Pharmacotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cognitive Behavioral Therapy (CBT) with Antidepressants
- Interpersonal Therapy (IPT) with Antipsychotics
- Psychodynamic Therapy with Mood Stabilizers
7. Dysthymia Market Regional And Country Analysis
- 7.1. Global Dysthymia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dysthymia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dysthymia Market
- 8.1. Asia-Pacific Dysthymia Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dysthymia Market
- 9.1. China Dysthymia Market Overview
- 9.2. China Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dysthymia Market
- 10.1. India Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dysthymia Market
- 11.1. Japan Dysthymia Market Overview
- 11.2. Japan Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dysthymia Market
- 12.1. Australia Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dysthymia Market
- 13.1. Indonesia Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dysthymia Market
- 14.1. South Korea Dysthymia Market Overview
- 14.2. South Korea Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dysthymia Market
- 15.1. Western Europe Dysthymia Market Overview
- 15.2. Western Europe Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dysthymia Market
- 16.1. UK Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dysthymia Market
- 17.1. Germany Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dysthymia Market
- 18.1. France Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dysthymia Market
- 19.1. Italy Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dysthymia Market
- 20.1. Spain Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dysthymia Market
- 21.1. Eastern Europe Dysthymia Market Overview
- 21.2. Eastern Europe Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dysthymia Market
- 22.1. Russia Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dysthymia Market
- 23.1. North America Dysthymia Market Overview
- 23.2. North America Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dysthymia Market
- 24.1. USA Dysthymia Market Overview
- 24.2. USA Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dysthymia Market
- 25.1. Canada Dysthymia Market Overview
- 25.2. Canada Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dysthymia Market
- 26.1. South America Dysthymia Market Overview
- 26.2. South America Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dysthymia Market
- 27.1. Brazil Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dysthymia Market
- 28.1. Middle East Dysthymia Market Overview
- 28.2. Middle East Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dysthymia Market
- 29.1. Africa Dysthymia Market Overview
- 29.2. Africa Dysthymia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dysthymia Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dysthymia Market, Segmentation By Comorbidities, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dysthymia Market Competitive Landscape And Company Profiles
- 30.1. Dysthymia Market Competitive Landscape
- 30.2. Dysthymia Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
31. Dysthymia Market Other Major And Innovative Companies
- 31.1. BristolMyers Squibb Company
- 31.2. AstraZeneca plc
- 31.3. Novartis International AG
- 31.4. Roche Holding AG
- 31.5. Takeda Pharmaceutical Company Limited
- 31.6. Eli Lilly and Company
- 31.7. Teva Pharmaceutical Industries Ltd.
- 31.8. Biogen Inc.
- 31.9. Horizon Therapeutics plc
- 31.10. Shionogi & Co. Ltd.
- 31.11. Jazz Pharmaceuticals
- 31.12. Ipsen SA
- 31.13. Cipla Limited
- 31.14. Lupin Pharmaceuticals
- 31.15. Mallinckrodt Pharmaceuticals
32. Global Dysthymia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dysthymia Market
34. Recent Developments In The Dysthymia Market
35. Dysthymia Market High Potential Countries, Segments and Strategies
- 35.1 Dysthymia Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dysthymia Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dysthymia Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
